Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature.

摘要: RATIONALE About one-third of the lung tumors are staged as locally advanced at time initial diagnosis; however, optimal induction treatment before curative resection has not been elucidated. To date, evidence regarding preoperative apatinib plus S-1 for pulmonary adenocarcinoma is scarce. PATIENT CONCERNS A 29-year-old female was admitted because persistent cough, sputum, and chest distress 2 months. DIAGNOSES Primary (cT3N2M0, IIIB) with unknown driver gene mutation status. INTERVENTIONS The patient had received 4 months neoadjuvant therapy using oral (425 mg daily) (60 mg, twice daily weeks a 2-week drug-free interval), followed by anatomical lobectomy intent. Adjuvant month, 250 mg another month) same dosage were administered Thereafter, maintenance low-dose monotherapy (40 interval) continued 6 OUTCOMES adverse events tolerable well-controlled. postoperative recurrence-free survival years half up to now indicated. LESSONS Preoperative showed efficacy in adenocarcinoma. However, high-quality trials warranted recommendation this therapeutic regimen.